Browse by Series:

COMBI-AD: Implications for Melanoma Patients

Insights From: Reinhard Dummer, MD, UC San Diego Moores Cancer Center
Published: Friday, Sep 22, 2017



Transcript: 

Reinhard Dummer, MD: The data of the COMBI-AD study are really a breakthrough. We will definitely use this combination for many, or most, BRAF-mutated patients after completion of surgery. The impact on major outcome is significant, so it’s very relevant. For us, this means that we will do molecular testing in every patient at stage 3. We will advise the patients how to start the treatment. It’s important that the patients know what the major adverse events are, and the major problem for this patient population is pyrexia—fever reactions. The best way to deal with this is to interrupt treatment early, wait until the fever is completely gone, and then restart. And in many patients, it will stay away. And then the tolerability is actually really good to excellent. Some patients really don’t even notice that they are on the medication. So, I think the quality of life will be very reasonable during this type of treatment.

The COMBI-AD study now offers a new treatment option for patients at a very high risk, and I’m sure that it will be accepted positively by the community.

Transcript Edited for Clarity 
SELECTED
LANGUAGE
Slider Left
Slider Right


Transcript: 

Reinhard Dummer, MD: The data of the COMBI-AD study are really a breakthrough. We will definitely use this combination for many, or most, BRAF-mutated patients after completion of surgery. The impact on major outcome is significant, so it’s very relevant. For us, this means that we will do molecular testing in every patient at stage 3. We will advise the patients how to start the treatment. It’s important that the patients know what the major adverse events are, and the major problem for this patient population is pyrexia—fever reactions. The best way to deal with this is to interrupt treatment early, wait until the fever is completely gone, and then restart. And in many patients, it will stay away. And then the tolerability is actually really good to excellent. Some patients really don’t even notice that they are on the medication. So, I think the quality of life will be very reasonable during this type of treatment.

The COMBI-AD study now offers a new treatment option for patients at a very high risk, and I’m sure that it will be accepted positively by the community.

Transcript Edited for Clarity 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x